Methylene Blue

Methylene blue is a bright blue dye that doctors have used for well over a hundred years. It has one solid, well-proven medical job — fixing a blood problem called methemoglobinemia — plus a few uses that hospitals are still testing. But none of that is why it is popular right now. Online, it is sold as a “nootropic” (a supposed brain booster), an energy aid for your cells, and an anti-aging compound. Today’s human evidence does not strongly back up those claims. This profile sorts out what the science actually shows from what the marketing promises.

What it is

Methylene blue’s full chemical name is methylthioninium chloride. It is a man-made phenothiazine dye (a family of synthetic dye chemicals), first made in 1876. It is a small molecule that works as a redox agent — meaning it shuttles electrons around (it can both take them and give them away). Its own FDA label flatly calls it an “oxidation-reduction agent.” It is not a peptide, and it is not a hormone or a SARM. The key to how it works is a simple trick: it flips back and forth between a blue form (MB+) and a colorless form (leucomethylene blue), picking up and dropping off electrons as it goes.

Here is what it is actually known to do in the body:

• It moves electrons inside your cells’ power plants — at low amounts, it can act as a backup electron carrier in the mitochondria (the parts of a cell that make energy), helping electrons get where they need to go even when the normal route is broken. This is the idea behind the claimed “mitochondrial” or “energy” effects.
• It turns broken hemoglobin back into the working kind — it converts methemoglobin (an iron form, Fe3+, that can’t carry oxygen well) back into normal hemoglobin (Fe2+) using a body process called NADPH-dependent reduction. This is its approved use.
• It blocks two signaling enzymes (nitric oxide synthase and soluble guanylate cyclase) — which is why hospitals are studying it for a kind of dangerous low blood pressure called distributive/vasoplegic shock.
• It blocks an enzyme called monoamine oxidase (MAO) — this one matters a lot. It strongly blocks the MAO-A type, and that is exactly what makes it risky to mix with certain drugs (see the serotonin syndrome warning below).

The claims

In biohacking, fitness, and longevity circles, people use methylene blue off-label (meaning for reasons it was never approved for) — often as an unregulated “research chemical,” a lozenge, or a troche (a tablet you let dissolve in your mouth). The claims are broad: sharper thinking and “nootropic” brain benefits, more “mitochondrial energy,” slower aging, better mood or antidepressant effects, antiviral or “immune” support, and faster athletic recovery. For the most part, these performance, longevity, and brain-boosting claims are not backed by solid human evidence.

What the evidence actually shows

• Methemoglobinemia (the approved use): Strong, long-settled science here. The FDA approved it as ProvayBlue for acquired methemoglobinemia in both adults and children (first U.S. approval in 2016).
• Ifosfamide-induced encephalopathy (brain confusion caused by a chemotherapy drug): Backed by case reports and observational studies, but not by randomized trials (the gold-standard kind of study).
• Vasoplegic syndrome / septic and post-cardiopulmonary-bypass shock (severe drops in blood pressure, including after heart-bypass surgery): Small trials and combined analyses suggest it helps with blood pressure (raising mean arterial pressure and cutting the need for blood-pressure-raising drugs), but there is no proof it helps people live longer. Still investigational and off-label.
• Cognition / Alzheimer’s: This is where the biohacker claims really come from. A close cousin of methylene blue called leuco-methylthioninium (LMTM / TRx0237) — a phenothiazine designed to target tau, a protein tangled up in Alzheimer’s — failed its main goals in a Phase 3 trial in mild-to-moderate Alzheimer’s (Gauthier et al., Lancet 2016). Separately, a small functional-MRI study in healthy adults (Rodriguez et al., Radiology 2016) — an fMRI is a brain scan that tracks activity — found short-term changes in brain activity and modest effects on attention and memory tasks. But that study was small, early-stage, and not proof that it boosts thinking in any meaningful way.
• Depression / bipolar: Only small, older studies exist — not enough to justify routine use.

Bottom line on the evidence: apart from methemoglobinemia (plus the investigational shock and ifosfamide-encephalopathy uses), the human evidence for the popular biohacking claims is weak, preliminary, or simply not there.

Legal and regulatory status

• FDA: Approved as a prescription drug for methemoglobinemia (ProvayBlue and older methylene blue injection products). It is a drug, not a legal dietary-supplement ingredient — so selling it as a supplement or “nootropic” with disease or structure/function claims falls outside what the FDA has approved. A lot of the “research-grade” or “USP” methylene blue sold online is not quality-checked for people to swallow.
• DEA: Not a controlled substance — it is not scheduled under the Controlled Substances Act.
• Anti-doping (WADA): Not on the WADA Prohibited List, and it doesn’t fall into any banned drug category (you can confirm this by its absence from the 2026 List).

Safety

• Serotonin syndrome — the most important known risk. Because methylene blue strongly blocks MAO-A, it can trigger serotonin toxicity (a dangerous buildup of the brain chemical serotonin) that can be deadly when mixed with serotonin-raising medicines (SSRIs/SNRIs, clomipramine, and others). The FDA put out a Drug Safety Communication about this in 2011.
• G6PD deficiency (a common inherited enzyme shortage) — it can cause hemolytic anemia (red blood cells breaking apart), and it also works less well at treating methemoglobinemia in these patients. It is either off-limits or used very carefully.
• Paradoxical methemoglobinemia — at high doses, it can actually cause the very blood problem it cures at normal doses.
• Dose-dependent effects — these can include hemolysis (red blood cells breaking down), dizziness, headache, shortness of breath, and confusion; high IV (intravenous, into a vein) doses can cause chest pain and high blood pressure.
• Harmless but worth knowing — it turns your urine and other fluids a blue-green color, and it can throw off pulse-oximeter readings (the finger clip that measures blood oxygen), briefly showing a falsely low number.
• Pregnancy — putting it into the amniotic fluid has, in the past, been linked to harm to the baby, so it is generally avoided.
• There is no good safety data on the long-term, do-it-yourself low-dose “biohacking” pattern, and the purity of consumer products is a genuine worry.

Bottom line

Methylene blue is a real drug with one strong, FDA-approved use (methemoglobinemia) and a few uses hospitals are still testing. The thinking, energy, and longevity claims that fuel its online popularity are not backed by solid human evidence — the most relevant Alzheimer’s-related Phase 3 trial of its close cousin failed, and the human brain data are small and early. It isn’t a scheduled drug and isn’t banned by WADA, but it carries serious, well-documented risks — especially deadly serotonin syndrome when combined with serotonin-raising drugs, and red-blood-cell breakdown in people with G6PD deficiency — and consumer-grade products aren’t quality-controlled for swallowing.

Evidence grade: 7/10 · Moderate. (Strong for the approved methemoglobinemia indication; the popular biohacking claims remain preliminary or unsupported.)

Sources

• ProvayBlue (methylene blue) injection — FDA prescribing information
• FDA approval letter, ProvayBlue (2016)
• FDA Drug Safety Communication on serotonergic CNS reactions (linezolid/methylene blue, 2011)
• Rodriguez P, et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. 2016
• PubMed record for the Rodriguez et al. Radiology study
• Gauthier S, et al. Phase 3 trial of LMTM (TRx0237) in mild-to-moderate Alzheimer’s disease. Lancet. 2016
• WADA 2026 Prohibited List (methylene blue absent / not prohibited)
• DEA Controlled Substance Schedules (methylene blue not listed)